Clinical trial · Interventional
Combination Therapy of Microwave Ablation and Cellular Immunotherapy for Hepatocellular Carcinoma
Combination Therapy of Microwave Ablation and Expanding Activated Autologous Lymphocytes for Hepatocellular Carcinoma
NCT02851784CI-TRIAL-00050454recruitingPhase 2 / Phase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 18, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260918-000001
Summary
Brief summary (as posted)
The study is to observe safety, survival effect and peripheral T-lymphocyte subsets of combination therapy with percutaneous microwave ablation (MWA) and adoptive immunotherapy in hepatocellular carcinoma(HCC).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| adoptive immunotherapy | Biological | — | UNRESOLVED |
| MWA | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- MWA only
- description
- The HCC patients will be treated only by MWA.No adoptive immunotherapy will be used.
- interventionNames
- Procedure: MWA
- type
- EXPERIMENTAL
- label
- MWA combined with immunotherapy
- description
- The HCC patients will be treated firstly by MWA, and then treated by courses of adoptive immunotherapy.
- interventionNames
- Biological: adoptive immunotherapy
- Procedure: MWA
Primary outcomes (1)
- measure
- Cumulative survival rates were calculated by the Kaplan-Meier method, and comparison between MWA and combination treatment will be done by the log-rank test.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1. single HCC of 5 cm or smaller; 2. three or fewer multiple HCC with a maximum dimension of 3 cm or less; 3. absence of portal vein thrombosis or extrahepatic metastases; 4. Child-Pugh classification A or B; 5. tumor accessible via a percutaneous approach. white blood cell count \>2 x 109/L, platelet count \>40 x 109/L,serum creatinine \<110 μmol/L, aspartate aminotransferase \<3 times the upper limit, serum bilirubin \<2.5 times the upper limit, prothrombin time \<19 seconds. Exclusion Criteria: 1. pregnant or breast-feeding; psychiatric problems, addiction, or any other disorder that prevented informed consent; 2. active uncontrolled infection; concurrent systemic corticosteroid treatment; 3. systemic autoimmune disease; 4. clinically significant ischemic heart disease or cardiac failure; 5. and chemotherapy or radiotherapy within the preceding 6 months
References
Publications (0)
Data not yet available
No reference posted for this study.